- Home
- IMOS vs PGEN Comparison
IMOS vs PGEN Comparison
Compare IMOS & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMOS | PGEN |
|---|---|---|
| Founded | 1997 | 1998 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2007 | 2013 |
Fundamental Metrics
Financial Performance| Metric | IMOS | PGEN |
|---|---|---|
| Price | $48.33 | $4.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 85.2K | ★ 2.9M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $21.75 | $1,115.92 |
| Revenue Next Year | $4.21 | $81.04 |
| P/E Ratio | $158.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.06 | $1.28 |
| 52 Week High | $61.27 | $5.47 |
Technical Indicators
Market Signals| Indicator | IMOS | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.63 | 53.54 |
| Support Level | $32.65 | $3.97 |
| Resistance Level | $51.08 | $4.40 |
| Average True Range (ATR) | 1.96 | 0.24 |
| MACD | -0.94 | -0.01 |
| Stochastic Oscillator | 18.79 | 34.78 |
Price Performance
Historical ComparisonAbout IMOS ChipMOS TECHNOLOGIES INC.
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.
About PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.